A concise review of current radiopharmaceuticals in tumor angiogenesis imaging

Current Pharmaceutical Design

Volumn 18, Issue 8, 2012, Pages 1032-1040

  Lu, Xia ^a,b,c   Wang, Rong Fu ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b BEIJING NORMAL UNIVERSITY   (China)

^c Radiology Center   (China)

Author keywords

Integrin v 3; Peptide RGD; Peptide RRL; Targeted therapy; Tumor angiogenesis; Tumor molecular imaging; Vascular endothelial growth factor; Vascular endothelial growth factor receptor

Indexed keywords

ARGINYLARGINYLLEUCINE; ARGINYLGLYCYLASPARTIC ACID; FLUORESCEIN ISOTHIOCYANATE; IODINE 131; PEPTIDE; RADIOPHARMACEUTICAL AGENT; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR; YTTRIUM 90;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; DIMERIZATION; HUMAN; MOLECULAR IMAGING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR ANGIOGENESIS IMAGING;

AMINO ACID SEQUENCE; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; INTEGRIN ALPHAVBETA3; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84863164777     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799315812     Document Type: Review

References (56)

1. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3(6): 401-10.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407(6801): 249-57.
3. Turkbey B, Kobayashi H, Ogawa M, Bernardo M, Choyke PL. Imaging of tumor angiogenesis: functional or targeted? AJR 2009; 193(2): 304-13.
4. Folkman J. Angiogenesis. Annu Rev Med 2006; 57: 1-18.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
6. Cai WB, Chen XY. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008; 49(suppl2): 113S-28S.
7. Shchors K and Evan G. Tumor angiogenesis: cause or consequence of cancer? Cancer Res 2007; 67(15): 7059-61.
8. Wagner HN. Advancing a molecular theory of disease. J Nucl Med 2008; 49(8): 15N-34N.
9. Foss CA, Mease RC, Fan H, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res 2005; 11(11): 4022-8.
10. Stupack DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol 2004; 64: 207-38.
11. Xiong JP, Stehle T, Goodman SL, Arnaout MA. Integrins, cations and ligands: making the connection. J Thromb Haemost 2003; 1(7): 1642-54.
12. Cristofanilli M, Charnsangavej C, Hortobagyi GN. Angiogenesis modulation in cancer research: novel clinical approaches. Nat Re-Dru Discov 2002; 1(6): 415-26.
13. Goligorsky MS, Kessler H, Romanov VI. Molecular mimicry of integrin ligation: therapeutic potential of arginine-glycine-aspartic acid (RGD) peptides. Nephrol Dial Transplant 1998; 13(2): 254-63.
14. 99mTc-RGD peptides for targeting of integrins in tumor angiogenesis. Anticancer Research 2006; 26(1A): 431-4.
15. Zhou Y, Chakraborty S, Liu S. Radiolabeled cyclic RGD peptides as radiotracers for imaging tumors and thrombosis by SPECT. Theranostics 2011; 1: 58-82.
16. 18F-labelled linear peptides. Eur J Nucl Med Mol Imag 2002; 29(6): 754-9.
17. 3 integrin related tumor imaging. Nucl Med Biol 2003; 30(1): 1-9.
18. 3 integrin antagonists: class of tracers for tumor targeting. J Nucl Med 1999; 40(6): 1061-71.
19. 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 2004; 31(1): 11-9.
20. 3 integrin binding peptides in a nude mouse model. Cancer Res 2002; 62(21): 6146-51.
21. 18F]Galacto-RGD. PLoS Med 2005; 2(3): e70.
22. Chen X, Sievers E, Hou Y, et al. Integrin alpha(v)beta(3) targeted imaging of lung cancer. Neoplasia 2005; 7(3): 271-9.
23. Psimadas D, Bouziotis P. Antiagiogenesis in cancer and its detection with radiolabeled biomolecules. Hell J Nucl Med 2005; 8(1): 5-11.
24. Kolmar H. Alternative binding proteins: biological activity and therapeutic potential of cystine-knot miniproteins. FEBS J 2008; 275(11): 2684-90.
25. Aumailley M, Gurrath M, Müller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides: strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 1991; 291(1): 50-4.
26. Gurrath M, Müller G, Kessler H, Aumailley M, Timpl R. Conformation activity studies of rationally designed potent anti-adhesive RGD peptides. Eur J Biochem 1992; 210(3): 911-21.
27. Pfaff M, Tangemann K, Müller G, et al. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha v beta 3 and alpha 5 beta 1 integrins. J Biol Chem 1994; 269(32): 20233-8.
28. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGDcontaining peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001; 42(2): 326-36.
29. 18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004; 15(1): 61-9.
30. 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7- triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med 2008; 49: 830-6.
31. Janssen M, Oyen WJ, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 2002; 17(6): 641-6.
32. 3 expression. Bioconjug Chem 2006; 17(4): 1069-76.
33. 18F-FRGD2. J Nucl Med 2006; 47(1): 113-21.
34. 3 integrin levels. Radiology 2011; 260(1): 182-91.
35. 3 integrin expression. J Nucl Med 2007; 48(7): 1162-71.
36. Brown CK, Modzelewski RA, Johnson CS, Wong MK. A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli peptide display library. Annals of Surgical Oncology 2000; 7(10): 743-9.
37. Weller GE, Wong MK, Modzelewski RA, et al. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. Cancer Res 2005; 65(2): 533-9.
38. Henry DO, Chen SC, Wong MK. Targeted molecular imaging of prostate cancer using tumor endothelium homing arg-arg-leu peptides. J Clin Oncol 2006; 24(18-suppl): 14582.
39. Yu MM, Wang RF, Yan P, Zhang CL, Liu M, Cui YG. Design, synthesis and iodination of an arg-arg-leu peptide for potential use as an imaging agent for human prostate carcinoma. J Label Compd Radiopharm 2008; 51(11): 374-8.
40. Wang RF, Yu MM, Lu X. A new tumor neovasculature imaging tracer: radioiodine labeled small peptide. J Nucl Med MEETING ABSTRACTS 2010; 51: 1116.
41. [Lu X, Yan P, Wang Rongfu, et al. The further study on radioiodinated peptide Arg-Arg-Leu targeted to neovascularization as well as tumor cells in molecular tumor imaging. J Radioanal Nucl Chem 2011; DOI 10.1007/s10967-011-1342-1.
42. Coleman CN. Linking radiation oncology and imaging through molecular biology (or now that therapy and diagnosis have separated, it's time to get together again!). Radiology 2003; 228(1): 29-35.
43. Li S, Radosavljevic M, Kienast O, et al. Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Annals of Oncology 2003; 14(8): 1274-7.
44. Li S, Peck-Radosavljevic M, Koller E, et al. Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int J Cancer 2001; 91(6): 789-96.
45. Welc MJ, Hawker CJ, and Wooley KL. The advantages of nanoparticles for PET. J Nucl Med 2009; 50(11): 1743-6.
46. 3-targeted, dual-modality micellar nanoprobes. Experimental Biology and Medicine 2010; 235: 957-65.
47. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002; 94(19): 1484-93.
48. Anderson CJ, Ferdani R Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm 2009; 24(4): 379-93.
49. Willmann JK, Kimura RH, Deshpande N, Lutz AM, Cochran JR, Gambhir SS. Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med 2010; 51(3): 433-40.
50. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002; 43(5): 693-713.
51. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004; 3(6): 488-99.
52. [Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9(6): 653-60.
53. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285(21): 1182-6.
54. Liu Z, Wang F, Chen X. Integrin targeted delivery of radiotherapeutics. Theranostics 2011; 1: 201-10.
55. 90Y-labeled two multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy. Mol Pharm 2011; 8(2): 591-9.
56. 111In-Labeled Abegrin™ in nude mouse models. Mol Imaging Biol 2011; 13(1): 112-20.